Ercan ÖĞREDEN, Bengi BAŞER, Emel KARAGÖZ, Ural OĞUZ, Ahmet KARAGÖZ, Alptekin TOSUN, Erhan DEMİRELLİ, Murat USTA, Mehmet KARADAYI, Mehmet Hicri KÖSEOĞLU, Orhan YALÇIN

Does dutasteride have any cardioprotective effect in elderly men? A prospective randomised controled study

Aim: To investigate whether the increased serum levels of testosterone secondary to Dutasteride therapy has any protective effecton cardiovascular system.Material and Methods: A prospective analysis of 50 patients diagnosed benign prostatic enlargement between May 2015 and May2017 was performed. After randomization 25 patients treated with daily administration of 0.5 mg dutasteride (Dutasteride Group),and 25 patients were not given dutasteride (Control Group). We analyzed some serum novel cardiaovascular marker levels at baselineand after 6 months of the treatment. Echocardiography, carotid intima-media thickness and brachial artery resistive index (RI) wereevaluated at baseline and after 6 months of the treatment.Statistical analyses were performed using SPSS, version 21. While “t test” was used for comparison the independent groups, pairedt test was used in the matched groups. Statistical significance was considered at p0.05). Additionally,echocardiographic parameters, carotid intima-media thickness and brachial artery RI were similar before and after dutasteridetratment.Conclusion: After the short-term use of dutasteride, there was not a statistically significant difference in serum Lp a, hs-CRP andNT-proBNP levels. Additionally, echocardiographic parameters, carotid intima-media thickness and brachial artery RI were alsosimilar.

PDF

___

1. Armeni E, Lambrinoudaki I. Androgens and cardiovascular disease in women and men. Maturitas 2017;104:54-72.
2. Souverein PC, Herings RM, De la Rosette JJ, et al. Evaluating adverse cardiovascular effects of drug treatment for benign prostatic hyperplasia (BPH): methodological considerations. J Clin Epidemiol 2001;54:518-24.
3. Chasland LC, Knuiman MW, Divitini ML, et al. Greater physical activity and higher androgen concentrations are independently associated with lower cardiometabolic risk in men. Clin Endocrinol (Oxf). 2017;87:466-74.
4. Traish AM, Haider A, Haider KS, et al. Long-Term Testosterone Therapy Improves Cardiometabolic Function and Reduces Risk of Cardiovascular Disease in Men with Hypogonadism: A Real-Life Observational Registry Study Setting Comparing Treated and Untreated (Control) Groups. J Cardiovasc Pharmacol Ther. 2017;22:414-33.
5. Pritchard CC, Nelson PS. Gene expression profiling in the developing prostate. Differentiation 2008;76:624- 40.
6. Chou CH, Lin CL, Lin MC, et al. 5α-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia. J Endocrinol Invest 2015;38:799-805.
7. Vigen R, O’Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013;310:1829-36.
8. Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One 2014;9:85805.
9. Ohlsson C, Barrett-Connor E, Bhasin S, et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden. J Am Coll Cardiol 2011;58:1674-81.
10. Carson CC, Rosano G. Exogenous testosterone, cardiovascular events, and cardiovascular risk factors in elderly men: a review of trial data. J Sex Med 2012;9:54-67.
11. Sharma R, Oni OA, Gupta K, et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J. 2015;36:2706-15.
12. Iellamo F, Volterrani M, Caminiti G, et al. Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study. J Am Coll Cardiol 2010;56:1310-6.
13. Caminiti G, Volterrani M, Iellamo F, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009;54:919-27.
14. Elkhoury FF, Rambhatla A, Mills JN, Rajfer J. Cardiovascular Health, Erectile Dysfunction, and Testosterone Replacement: Controversies and Correlations. Urology 2017;110:1-8.
15. Rovira-Llopis S, Bañuls C, de Marañon AM, et al. Low testosterone levels are related to oxidative stress, mitochondrial dysfunction and altered subclinical atherosclerotic markers in type 2 diabetic male patients. Free Radic Biol Med 2017;108:155-62.
16. Ohlsson C, Barrett-Connor E, Bhasin S, et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden. J Am Coll Cardiol. 2011;58:1674-81.
17. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. Journal of Urology. 2009;181:1998-2006.
18. Keating NL, O’Malley AJ, Freedland SJ, et al. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. Journal of the National Cancer Institute 2010;102:39-46.
19. Jespersen CG, Norgaard M, Borre M. Androgendeprivation Therapy in Treatment of Prostate Cancer and Risk of Myocardial Infarction and Stroke: A Nationwide Danish Population-based Cohort Study. Eur Urol 2014;65:704-9.
20. Souverein PC, Herings RM, Man in ‘t Veld AJ, et al. Study of the association between ischemic heart disease and use of alpha-blockers and finasteride indicated for the treatment of benign prostatic hyperplasia. Eur Urol. 2002;42:254-61.
21. Hsieh TF, Yang YW, Lee SS, et al. Use of 5-alphareductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study. PLoS One 2015;10:0119694.
22. Skeldon SC, Macdonald EM, Law MR, et al. The Cardiovascular Safety of Dutasteride. J Urol. 2017;197:1309-14.
23. Wang Y, Ma H, Yang J, et al. Lipoprotein(a) is associated with left ventricular systolic dysfunction in a Chinese population of patients with hypertension and without coronary artery disease. Arch Med Sci. 2017;13:1078- 85.
24. Saeed A, Virani SS. Lipoprotein(a) and cardiovascular disease: current state and future directions for an enigmatic lipoprotein. Front Biosci (Landmark Ed) 2018;23:1099-112.
25. Lepojärvi ES, Huikuri HV, Piira OP, et al. Biomarkers as predictors of sudden cardiac death in coronary artery disease patients with preserved left ventricular function (ARTEMIS study). PLoS One 2018;13:0203363.
26. Seo WW, Kim HL, Kim YJ, et al. Incremental prognostic value of high-sensitive C-reactive protein in patients undergoing coronary computed tomography angiography. J Cardiol 2016;68:222-8.
27. Xu L, Chen Y, Ji Y, et al. Influencing factors of NTproBNP level inheart failure patients with different cardiacfunctions and correlation with prognosis. Exp Ther Med 2018;15:5275-80.
28. Korkmaz H, Akbulut M, Ozbay Y, et al. A new noninvasive method in evaluating the endothelial function: the measurement of the resistive index after reactive hyperemia of the brachial artery. Echocardiography 2010;27:873-7.
29. Mookadam F, Moustafa SE, Lester SJ, et al. Subclinical atherosclerosis: Evolving the role of carotid intimamedia thickness. Prev Cardiol 2010;13:186-97.
30. Mahat RK, Singh N, Rathore V, et al. Relationship between Atherogenic Indices and Carotid IntimaMedia Thickness in Prediabetes: A Cross-Sectional Study from Central India. Med Sci (Basel) 2018;6:55.